Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 43: EUROPA-Studie - Sekundäre Endpunkte Abb. 44: EUROPA-Studie - Myokardinfarkt Abb. 45: EUROPA-Studie - Hospitalisierung Aktuelles Bild - Abb. 46: EUROPA-Studie - Blutdruck Abb. 47: EUROPA-Studie - Compliance Abb. 48: EUROPA-Studie - Non Compliance Abb. 49: EUROPA-Studie - Klinische Aussagen Zum letzten Bild
Abbildung 46: EUROPA-Studie - Blutdruck
During the run-in period during where all patients received perindopril, blood pressure was reduced from 137/82 to 128/78 mm Hg. After randomisation, systolic and diastolic blood pressures among patients treated with perindopril were maintained until the study end and the average blood pressure during double-blind treatment was 5/2 mm Hg higher in the placebo group. Also, it was shown that reduction of fatal and non-fatal MI was reduced more then due to the reduction of BP alone (ref. EUROPA editorial).
 
EUROPA-Studie - Blutdruck
Vorheriges Bild Nächstes Bild   


Abbildung 46: EUROPA-Studie - Blutdruck
During the run-in period during where all patients received perindopril, blood pressure was reduced from 137/82 to 128/78 mm Hg. After randomisation, systolic and diastolic blood pressures among patients treated with perindopril were maintained until the study end and the average blood pressure during double-blind treatment was 5/2 mm Hg higher in the placebo group. Also, it was shown that reduction of fatal and non-fatal MI was reduced more then due to the reduction of BP alone (ref. EUROPA editorial).
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung